Trodelvy
Sacituzumab Govitecan
Why Trodelvy Costs $15,643.00 Per Claim
Trodelvy (Sacituzumab Govitecan) is used to treat cancer. According to CMS Medicare Part D spending data, the program spent $876.0M on this drug, covering 6,400 beneficiaries across 56,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Sacituzumab Govitecan or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Trodelvy increased by +68.4% year-over-year, driven by rapidly growing utilization and potential price increases.
Price Breakdown
Drug Details
Frequently Asked Questions
Trodelvy (Sacituzumab Govitecan) costs an average of $15,643.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $136,875.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Yes, a generic version of Trodelvy (Sacituzumab Govitecan) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Sacituzumab Govitecan.
Medicare Part D spent $876.0M on Trodelvy, covering 6,400 beneficiaries across 56,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Sacituzumab Govitecan, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.